Drug Profile

R 5780

Alternative Names: R-5780

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rise Therapeutics
Class Antineoplastics; Immunotherapies; Proteins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

21 Jan 2025 Rise Therapeutics plans a phase I rial for Solid tumours (Combination therapy, Unresectable/Inoperable, Late-stage disease, Second-line therapy or greater) (PO) in March 2025 (NCT06398418)
13 Jan 2025 R 5780 receives FDA Investigational new drug application clearance for Cancer
03 Jan 2023 R 5780 is available for licensing as of 03 Jan 2023. https://risetherapeutics.com/capabilities

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com